Medivation Inc (MDVN) : Havens Advisors added new position in Medivation Inc during the most recent quarter end. The investment management firm now holds 183,500 shares of Medivation Inc which is valued at $11,298,095 , the company said in a statement filed on Jul 13, 2016 with the SEC.Medivation Inc makes up approximately 9.85% of Havens Advisors’s portfolio.
Other Hedge Funds, Including , Capstone Asset Management Co reduced its stake in MDVN by selling 270 shares or 4.57% in the most recent quarter. The Hedge Fund company now holds 5,634 shares of MDVN which is valued at $346,885. Medivation Inc makes up approx 0.01% of Capstone Asset Management Co’s portfolio.Creative Planning reduced its stake in MDVN by selling 8,640 shares or 68.92% in the most recent quarter. The Hedge Fund company now holds 3,897 shares of MDVN which is valued at $239,938.British Columbia Investment Management Corp boosted its stake in MDVN in the latest quarter, The investment management firm added 278 additional shares and now holds a total of 76,869 shares of Medivation Inc which is valued at $4,773,565. Medivation Inc makes up approx 0.04% of British Columbia Investment Management Corp’s portfolio.F&v Capital Management boosted its stake in MDVN in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 6,260 shares of Medivation Inc which is valued at $388,746. Medivation Inc makes up approx 0.28% of F&v Capital Management’s portfolio. Mazama Capital Management Inc added MDVN to its portfolio by purchasing 5,217 company shares during the most recent quarter which is valued at $323,976. Medivation Inc makes up approx 0.06% of Mazama Capital Management Inc’s portfolio.
Medivation Inc closed down -0.05 points or -0.08% at $61.83 with 7,02,671 shares getting traded on Monday. Post opening the session at $61.88, the shares hit an intraday low of $61.533 and an intraday high of $62.14 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Medivation Inc reported $0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $0.23. The company had revenue of $182.50 million for the quarter, compared to analysts expectations of $197.72 million. The company’s revenue was up 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.
Many Wall Street Analysts have commented on Medivation Inc. Company shares were Reiterated by Wedbush on Jul 12, 2016 to “Outperform”, Firm has raised the Price Target to $ 66 from a previous price target of $63 .Company shares were Reiterated by Barclays on May 6, 2016 to “Overweight”, Firm has raised the Price Target to $ 70 from a previous price target of $48 .Medivation Inc was Upgraded by Citigroup to ” Buy” on May 6, 2016.
Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.